Tvardi Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $25.1M
- Price
- $1.88
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.05%
- Volume
- 201.9K
About
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
Quick stats
Shares outstanding13.3M
Computed float12.5M
Float / shares93.7%
Cash runway (months)9.6
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001346830
AI Summary
AI-generated1/12
standardbullishearnings
Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update
Tvardi announced positive topline results from a healthy volunteer study of its STAT3 inhibitor TTI-109, confirming the prodrug design and improved tolerability, and selected ulcerative colitis (UC) as the initial indication.
Financial results for the second quarter of 2026 showed R&D expenses of $4.0 million and G&A expenses of $2.6 million, resulting in a net loss of $6.5 million or $(0.69) per share.
The company reported cash, cash equivalents and short-term investments of $15.8 million as of June 30, 2026, down from $30.8 million at year-end 2025, and noted that advancing TTI-109 into UC will require additional funding and IND clearance.
Red flags
- Cash balance dropped approximately 50% in six months to $15.8 million
- Company stated that advancing TTI-109 into UC will require additional funding